Phase 2b/3 Trial Shows Efficacy of Filgotinib for the Induction and Maintenance of Remission in Moderately and Severely Active Ulcerative Colitis
N/A
Provided Content: Content provided by Business Wire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
